BACKGROUND/AIMS: Antibodies to @entity375 are associated with @entity30 . The aim of this study was to assess the sensitivity and specificity of antibodies to @entity375 for @entity30 in an Italian population and to evaluate their clinical role. METHODOLOGY: Antibodies to @entity375 cerevisiae serum levels were assessed in 72 @entity29 @entity1 (30 @entity30 ; 42 @entity31 ) and 35 age-matched controls. @entity1 were divided into subgroups on the basis of disease behavior and clinical feature were evaluated. RESULTS: Antibodies to @entity375 sensitivity and specificity for @entity30 @entity1 were 50% (31-68) and 91% (77-98), for IgG and 56% (37-64) and 94% (80-99), respectively, for IgA. No correlation was observed between the presence of antibodies to @entity375 and clinical features. Antibodies to @entity375 were more prevalent in @entity30 than in @entity31 @entity1 (IgA: 57% vs. 26%; IgG: 50% vs. 17%; p < 0.05). Interestingly, in @entity30 @entity1 , the prevalence of antibodies to @entity375 was higher in @entity1 with small bowel involvement than in @entity1 with pure @entity1049 (IgA: 66% vs. 17%; IgG: 58% vs. 17%). No difference in antibodies to @entity375 prevalence was observed between @entity31 and pure @entity30 @entity1 . CONCLUSIONS: Our data show an association between @entity30 and antibodies to @entity375 . However, it does not seem useful in discriminating between @entity31 and colic @entity30 .

Antibodies to XXXX : are they useful in clinical practice?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity375 :: ('4932', 'Species') :: ['Saccharomyces', 'Saccharomyces cerevisiae'] @entity30 :: ('MESH:D003424', 'Disease') :: ["colonic Crohn's disease", "Crohn's disease"] @entity1049 :: ('MESH:D003108', 'Disease') :: ['colonic disease']
@entity375 :: (4932,Species) :: ['Saccharomyces cerevisiae']
